Clinical trials in Salzburg – page 10

285 clinical trials in Salzburg, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salzburg at a glance

285

clinical trials

Research sites4

Quick filters

285 trials in Salzburg

Open in trial search

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:DNTH103
Sponsor:Dianthus Therapeutics Inc.

Contact Research Centre

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:ORG-129
Sponsor:Agomab Spain S.L.U.

Contact Research Centre

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Erysipelas

Not yet recruiting

A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

Registered drugNo placebo

A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Dalbavancin
Sponsor:Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Contact Research Centre

Chronic rhinosinusitis with nasal polyps

Not yet recruiting

Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

Registered drugNo placebo

Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Medical University Of Vienna

Contact Research Centre

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Not yet recruiting

Registered drugNo placebo

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:CC-97540
Sponsor:Celgene Corp.

Contact Research Centre

Pancreatic carcinoma metastatic

Not yet recruiting

Study of M9140 for Patients With Advanced Pancreatic Cancer

InvestigationalNo placebo

Study of M9140 for Patients With Advanced Pancreatic Cancer

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Salzburg

What the registry says about research in the country

01 Oncology Research

Comprehensive studies focusing on metastatic cancers and innovative treatment approaches, including trials investigating new therapies for prostate cancer, colorectal cancer, and bladder cancer.

Advanced cancer treatments
Immunotherapy combinations
Novel therapeutic agents

Multiple clinical trials evaluating targeted therapies and combination treatments for various stages of cancer progression.

02 Hematological Studies

Investigating breakthrough treatments for multiple myeloma and acute myeloid leukemia, with emphasis on innovative therapeutic combinations and targeted approaches.

Blood cancer therapies
Novel drug combinations
Treatment resistance studies

Focus on improving outcomes for patients with various blood disorders through advanced therapeutic strategies.

03 Chronic Disease Management

Research initiatives addressing cardiovascular disease, Crohn's disease, and Alzheimer's disease, exploring new treatment modalities and therapeutic approaches.

Inflammatory conditions
Cardiovascular health
Neurological disorders

Comprehensive studies aimed at developing more effective treatments for chronic conditions affecting quality of life.

Back to Austria All countries